Additional phase II data backs up Bavarian Nordic's Covid-19 vaccine

Bavarian Nordic is on track with its plan to start phase III trials of its corona vaccine candidate in the first half of this year. New data released on Monday is promising for the candidate.
Photo: Philip Davali/Ekstra Bladet, Philip Davali
Photo: Philip Davali/Ekstra Bladet, Philip Davali
by marketwire, translated by catherine brett and daniel pedersen

Danish biotech company Bavarian Nordic can once again announce positive results from a phase II study of its corona vaccine, ANBCoV2. The results from two remaining patient groups have now been analyzed and found to support the vaccine’s ability to boost neutralizing antibodies to levels that protect the individual against Covid-19.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
  • Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
    Must contain at least 2 characters
    Must contain at least 2 characters

    Get full access for you and your coworkers

    Start a free company trial today

    Share article

    Sign up for our newsletter

    Stay ahead of development by receiving our newsletter on the latest sector knowledge.

    Newsletter terms

    Front page now

    Further reading